Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Correction to The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.

Sandoval E, Lafuente-Monasterio MJ, Almela MJ, Castañeda P, Jiménez Díaz MB, Martínez-Martínez MS, Vidal J, Angulo-Barturen Í, Bamborough P, Burrows J, Cammack N, Chaparro MJ, Coterón JM, de Cozar C, Crespo B, Díaz B, Drewes G, Fernández E, Ferrer-Bazaga S, Fraile MT, Gamo FJ, Ghidelli-Disse S, Gómez R, Haselden J, Huss S, León ML, de Mercado J, Macdonald SJF, Martín Hernando JI, Prats S, Puente M, Rodríguez A, de la Rosa JC, Rueda L, Selenski C, Willis P, Wilson DM, Witty M, Calderón F.

J Med Chem. 2017 Dec 14;60(23):9911. doi: 10.1021/acs.jmedchem.7b01491. Epub 2017 Nov 22. No abstract available.

PMID:
29164877
2.

The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.

Sandoval E, Lafuente-Monasterio MJ, Almela MJ, Castañeda P, Jiménez Díaz MB, Martínez-Martínez MS, Vidal J, Angulo-Barturen Í, Bamborough P, Burrows J, Cammack N, Chaparro MJ, Coterón JM, de Cozar C, Crespo B, Díaz B, Drewes G, Fernández E, Ferrer-Bazaga S, Fraile MT, Gamo FJ, Ghidelli-Disse S, Gómez R, Haselden J, Huss S, León ML, de Mercado J, Macdonald SJF, Martín Hernando JI, Prats S, Puente M, Rodríguez A, de la Rosa JC, Rueda L, Selenski C, Willis P, Wilson DM, Witty M, Calderón F.

J Med Chem. 2017 Aug 24;60(16):6880-6896. doi: 10.1021/acs.jmedchem.6b01441. Epub 2017 Aug 14. Erratum in: J Med Chem. 2017 Dec 14;60(23):9911.

PMID:
28806082
3.

Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosis.

Warrier T, Martinez-Hoyos M, Marin-Amieva M, Colmenarejo G, Porras-De Francisco E, Alvarez-Pedraglio AI, Fraile-Gabaldon MT, Torres-Gomez PA, Lopez-Quezada L, Gold B, Roberts J, Ling Y, Somersan-Karakaya S, Little D, Cammack N, Nathan C, Mendoza-Losana A.

ACS Infect Dis. 2015 Dec 11;1(12):580-5. doi: 10.1021/acsinfecdis.5b00025. Epub 2015 Jun 22.

PMID:
27623055
4.

Identification of KasA as the cellular target of an anti-tubercular scaffold.

Abrahams KA, Chung CW, Ghidelli-Disse S, Rullas J, Rebollo-López MJ, Gurcha SS, Cox JA, Mendoza A, Jiménez-Navarro E, Martínez-Martínez MS, Neu M, Shillings A, Homes P, Argyrou A, Casanueva R, Loman NJ, Moynihan PJ, Lelièvre J, Selenski C, Axtman M, Kremer L, Bantscheff M, Angulo-Barturen I, Izquierdo MC, Cammack NC, Drewes G, Ballell L, Barros D, Besra GS, Bates RH.

Nat Commun. 2016 Sep 1;7:12581. doi: 10.1038/ncomms12581.

5.

THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria.

Cox JA, Abrahams KA, Alemparte C, Ghidelli-Disse S, Rullas J, Angulo-Barturen I, Singh A, Gurcha SS, Nataraj V, Bethell S, Remuiñán MJ, Encinas L, Jervis PJ, Cammack NC, Bhatt A, Kruse U, Bantscheff M, Fütterer K, Barros D, Ballell L, Drewes G, Besra GS.

Nat Microbiol. 2016 Jan 18;1:15006. doi: 10.1038/nmicrobiol.2015.6.

PMID:
27571973
6.

Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases.

Ballell L, Strange M, Cammack N, Fairlamb AH, Borysiewicz L.

Nat Rev Drug Discov. 2016 Apr;15(4):292. doi: 10.1038/nrd.2016.51. Epub 2016 Mar 29. No abstract available.

PMID:
27020099
7.

Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery.

Rebollo-Lopez MJ, Lelièvre J, Alvarez-Gomez D, Castro-Pichel J, Martínez-Jiménez F, Papadatos G, Kumar V, Colmenarejo G, Mugumbate G, Hurle M, Barroso V, Young RJ, Martinez-Hoyos M, González del Río R, Bates RH, Lopez-Roman EM, Mendoza-Losana A, Brown JR, Alvarez-Ruiz E, Marti-Renom MA, Overington JP, Cammack N, Ballell L, Barros-Aguire D.

PLoS One. 2015 Dec 7;10(12):e0142293. doi: 10.1371/journal.pone.0142293. eCollection 2015.

8.

Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives.

Chaparro MJ, Vidal J, Angulo-Barturen I, Bueno JM, Burrows J, Cammack N, Castañeda P, Colmenarejo G, Coterón JM, de Las Heras L, Fernández E, Ferrer S, Gabarró R, Gamo FJ, García M, Jiménez-Díaz MB, Lafuente MJ, León ML, Martínez MS, Minick D, Prats S, Puente M, Rueda L, Sandoval E, Santos-Villarejo A, Witty M, Calderón F.

ACS Med Chem Lett. 2014 Mar 26;5(6):657-61. doi: 10.1021/ml500015r. eCollection 2014 Jun 12.

9.

Program and practice elements for placement prevention: a review of interventions and their effectiveness in promoting home-based care.

Lee BR, Ebesutani C, Kolivoski KM, Becker KD, Lindsey MA, Brandt NE, Cammack N, Strieder FH, Chorpita BF, Barth RP.

Am J Orthopsychiatry. 2014 May;84(3):244-56. doi: 10.1037/h0099811. Review.

PMID:
24827019
10.

Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3.

Remuiñán MJ, Pérez-Herrán E, Rullás J, Alemparte C, Martínez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jiménez E, Ortega-Muro F, Fraile-Gabaldón MT, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Minick DJ, Cacho M, Rebollo-López MJ, González C, Sousa V, Angulo-Barturen I, Mendoza-Losana A, Barros D, Besra GS, Ballell L, Cammack N.

PLoS One. 2013 Apr 17;8(4):e60933. doi: 10.1371/journal.pone.0060933. Print 2013.

11.

Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.

Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, Barroso V, Blanco D, Crespo B, Escribano J, González R, Lozano S, Huss S, Santos-Villarejo A, Martín-Plaza JJ, Mendoza A, Rebollo-Lopez MJ, Remuiñan-Blanco M, Lavandera JL, Pérez-Herran E, Gamo-Benito FJ, García-Bustos JF, Barros D, Castro JP, Cammack N.

ChemMedChem. 2013 Feb;8(2):313-21. doi: 10.1002/cmdc.201200428. Epub 2013 Jan 10.

12.

Relationship proximity to victims of witnessed community violence: associations with adolescent internalizing and externalizing behaviors.

Lambert SF, Boyd RC, Cammack NL, Ialongo NS.

Am J Orthopsychiatry. 2012 Jan;82(1):1-9. doi: 10.1111/j.1939-0025.2011.01135.x.

13.

Microbiology. Exploiting malaria drug resistance to our advantage.

Cammack N.

Science. 2011 Aug 5;333(6043):705-6. doi: 10.1126/science.1210875. No abstract available.

PMID:
21817037
14.

Examining the developmental process of risk for exposure to community violence among urban youth.

Lambert SF, Bradshaw CP, Cammack NL, Ialongo NS.

J Prev Interv Community. 2011;39(2):98-113. doi: 10.1080/10852352.2011.556558.

15.

Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, Schäfer W, Ji C, Heilek G, Cammack N, Brandt M, Umana P, Brinkmann U.

Antimicrob Agents Chemother. 2011 May;55(5):2369-78. doi: 10.1128/AAC.00215-10. Epub 2011 Feb 7.

16.

DISCREPANCIES BETWEEN COMMUNITY VIOLENCE EXPOSURE AND PERCEIVED NEIGHBORHOOD VIOLENCE.

Cammack NL, Lambert SF, Ialongo NS.

J Community Psychol. 2011 Jan 1;39(1):106-120. Epub 2010 Dec 2.

17.

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.

Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, Berrey M, Symonds B, De La Rosa A, Cammack N, Nájera I.

J Infect Dis. 2010 Nov 15;202(10):1510-9. doi: 10.1086/656774. Epub 2010 Oct 13.

PMID:
20942646
18.

In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.

Javanbakht H, Ptak RG, Chow E, Yan JM, Russell JD, Mankowski MK, Hogan PA, Hogg JH, Vora H, Hang JQ, Li Y, Su G, Paul A, Cammack N, Klumpp K, Heilek G.

Antiviral Res. 2010 May;86(2):212-9. doi: 10.1016/j.antiviral.2010.02.323. Epub 2010 Feb 26.

PMID:
20219553
19.

Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies.

Jekle A, Chhabra M, Lochner A, Meier S, Chow E, Brandt M, Sankuratri S, Cammack N, Heilek G.

Antimicrob Agents Chemother. 2010 Feb;54(2):734-41. doi: 10.1128/AAC.00841-09. Epub 2009 Dec 7.

20.

Modulation of alpha interferon anti-hepatitis C virus activity by ISG15.

Chua PK, McCown MF, Rajyaguru S, Kular S, Varma R, Symons J, Chiu SS, Cammack N, Nájera I.

J Gen Virol. 2009 Dec;90(Pt 12):2929-39. doi: 10.1099/vir.0.013128-0. Epub 2009 Aug 5.

PMID:
19656964
21.

CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.

Jekle A, Chow E, Kopetzki E, Ji C, Yan MJ, Nguyen R, Sankuratri S, Cammack N, Heilek G.

Antiviral Res. 2009 Sep;83(3):257-66. doi: 10.1016/j.antiviral.2009.06.005. Epub 2009 Jun 25.

PMID:
19559732
22.

The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine.

Smith DB, Kalayanov G, Sund C, Winqvist A, Maltseva T, Leveque VJ, Rajyaguru S, Le Pogam S, Najera I, Benkestock K, Zhou XX, Kaiser AC, Maag H, Cammack N, Martin JA, Swallow S, Johansson NG, Klumpp K, Smith M.

J Med Chem. 2009 May 14;52(9):2971-8. doi: 10.1021/jm801595c.

PMID:
19341305
23.

GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.

McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I.

Antimicrob Agents Chemother. 2009 May;53(5):2129-32. doi: 10.1128/AAC.01598-08. Epub 2009 Mar 9.

24.

Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Hang JQ, Yang Y, Harris SF, Leveque V, Whittington HJ, Rajyaguru S, Ao-Ieong G, McCown MF, Wong A, Giannetti AM, Le Pogam S, Talamás F, Cammack N, Nájera I, Klumpp K.

J Biol Chem. 2009 Jun 5;284(23):15517-29. doi: 10.1074/jbc.M808889200. Epub 2009 Feb 26.

25.

CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.

Ji C, Kopetzki E, Jekle A, Stubenrauch KG, Liu X, Zhang J, Rao E, Schlothauer T, Fischer S, Cammack N, Heilek G, Ries S, Sankuratri S.

J Biol Chem. 2009 Feb 20;284(8):5175-85. doi: 10.1074/jbc.M808745200. Epub 2008 Dec 19.

26.

The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.

Smith DB, Kalayanov G, Sund C, Winqvist A, Pinho P, Maltseva T, Morisson V, Leveque V, Rajyaguru S, Le Pogam S, Najera I, Benkestock K, Zhou XX, Maag H, Cammack N, Martin JA, Swallow S, Johansson NG, Klumpp K, Smith M.

J Med Chem. 2009 Jan 8;52(1):219-23. doi: 10.1021/jm800981y.

PMID:
19055482
27.

Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.

Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WR.

Antimicrob Agents Chemother. 2008 Dec;52(12):4356-69. doi: 10.1128/AAC.00444-08. Epub 2008 Oct 6.

28.

Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.

Bai X, Wilson KL, Seedorff JE, Ahrens D, Green J, Davison DK, Jin L, Stanfield-Oakley SA, Mosier SM, Melby TE, Cammack N, Wang Z, Greenberg ML, Dwyer JJ.

Biochemistry. 2008 Jun 24;47(25):6662-70. doi: 10.1021/bi702509d.

PMID:
18507398
29.

Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.

Kopetzki E, Jekle A, Ji C, Rao E, Zhang J, Fischer S, Cammack N, Sankuratri S, Heilek G.

Virol J. 2008 May 1;5:56. doi: 10.1186/1743-422X-5-56.

30.

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.

Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I.

J Antimicrob Chemother. 2008 Jun;61(6):1205-16. doi: 10.1093/jac/dkn085. Epub 2008 Mar 13.

PMID:
18343801
31.

The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.

McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I.

Antimicrob Agents Chemother. 2008 May;52(5):1604-12. doi: 10.1128/AAC.01317-07. Epub 2008 Feb 19.

32.

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

Melby T, Demasi R, Cammack N, Miralles GD, Greenberg ML.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1366-73. doi: 10.1089/aid.2006.0277.

PMID:
18184079
33.

2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.

Klumpp K, Kalayanov G, Ma H, Le Pogam S, Leveque V, Jiang WR, Inocencio N, De Witte A, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Winqist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB.

J Biol Chem. 2008 Jan 25;283(4):2167-75. Epub 2007 Nov 14.

34.

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.

Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, Masjedizadeh M, Smith DB, Cammack N, Klumpp K, Symons J.

J Biol Chem. 2007 Oct 12;282(41):29812-20. Epub 2007 Aug 13.

35.

Qualitative study of suicidality and help-seeking behaviors in African American adolescents.

Molock SD, Barksdale C, Matlin S, Puri R, Cammack N, Spann M.

Am J Community Psychol. 2007 Sep;40(1-2):52-63.

PMID:
17570053
36.

CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.

Ji C, Zhang J, Dioszegi M, Chiu S, Rao E, Derosier A, Cammack N, Brandt M, Sankuratri S.

Mol Pharmacol. 2007 Jul;72(1):18-28. Epub 2007 Mar 28.

PMID:
17392523
37.

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Le Pogam S, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N.

Bioorg Med Chem Lett. 2007 May 1;17(9):2570-6. Epub 2007 Feb 4.

PMID:
17317178
38.

The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.

Zhang J, Rao E, Dioszegi M, Kondru R, DeRosier A, Chan E, Schwoerer S, Cammack N, Brandt M, Sankuratri S, Ji C.

Antimicrob Agents Chemother. 2007 Apr;51(4):1386-97. Epub 2007 Jan 22.

39.

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA.

PLoS Med. 2007 Jan;4(1):e36.

40.

Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities.

Ji C, Brandt M, Dioszegi M, Jekle A, Schwoerer S, Challand S, Zhang J, Chen Y, Zautke L, Achhammer G, Baehner M, Kroetz S, Heilek-Snyder G, Schumacher R, Cammack N, Sankuratri S.

Antiviral Res. 2007 May;74(2):125-37. Epub 2006 Dec 5.

PMID:
17166600
41.

Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Hang JQ, Li Y, Yang Y, Cammack N, Mirzadegan T, Klumpp K.

Biochem Biophys Res Commun. 2007 Jan 12;352(2):341-50. Epub 2006 Nov 14.

PMID:
17113568
42.

Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors.

Chan E, Heilek-Snyder G, Cammack N, Sankuratri S, Ji C.

J Biomol Screen. 2006 Sep;11(6):652-63. Epub 2006 Jul 14.

PMID:
16844967
43.

Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.

Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, Jiang WR, Rajyaguru S, Tavares G, Oshiro C, Hendricks T, Klumpp K, Symons J, Browner MF, Cammack N, Nájera I.

J Virol. 2006 Jun;80(12):6146-54.

44.

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance.

Le Pogam S, Jiang WR, Leveque V, Rajyaguru S, Ma H, Kang H, Jiang S, Singer M, Ali S, Klumpp K, Smith D, Symons J, Cammack N, Nájera I.

Virology. 2006 Aug 1;351(2):349-59. Epub 2006 May 19.

45.

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

Melby T, Sista P, DeMasi R, Kirkland T, Roberts N, Salgo M, Heilek-Snyder G, Cammack N, Matthews TJ, Greenberg ML.

AIDS Res Hum Retroviruses. 2006 May;22(5):375-85.

PMID:
16706613
46.

Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.

Prabu-Jeyabalan M, King NM, Nalivaika EA, Heilek-Snyder G, Cammack N, Schiffer CA.

Antimicrob Agents Chemother. 2006 Apr;50(4):1518-21.

47.

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.

Klumpp K, Lévêque V, Le Pogam S, Ma H, Jiang WR, Kang H, Granycome C, Singer M, Laxton C, Hang JQ, Sarma K, Smith DB, Heindl D, Hobbs CJ, Merrett JH, Symons J, Cammack N, Martin JA, Devos R, Nájera I.

J Biol Chem. 2006 Feb 17;281(7):3793-9. Epub 2005 Nov 29.

48.

Development of a novel dual CCR5-dependent and CXCR4-dependent cell-cell fusion assay system with inducible gp160 expression.

Ji C, Zhang J, Cammack N, Sankuratri S.

J Biomol Screen. 2006 Feb;11(1):65-74. Epub 2005 Nov 28.

PMID:
16314403
49.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

50.

Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

Ma H, Leveque V, De Witte A, Li W, Hendricks T, Clausen SM, Cammack N, Klumpp K.

Virology. 2005 Feb 5;332(1):8-15.

Supplemental Content

Loading ...
Support Center